The type I interferon response in COVID-19: implications for treatment
Despite early reports to the contrary, there is increasing evidence that patients with severe COVID-19 have a robust type I interferon response, which contrasts with the delayed, possibly suppressed, interferon response seen early in infection. A robust type I interferon response could exacerbate hy...
Gespeichert in:
| Veröffentlicht in: | Nature reviews. Immunology 2020-10, Vol.20 (10), p.585-586 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 586 |
|---|---|
| container_issue | 10 |
| container_start_page | 585 |
| container_title | Nature reviews. Immunology |
| container_volume | 20 |
| creator | Lee, Jeong Seok Shin, Eui-Cheol |
| description | Despite early reports to the contrary, there is increasing evidence that patients with severe COVID-19 have a robust type I interferon response, which contrasts with the delayed, possibly suppressed, interferon response seen early in infection. A robust type I interferon response could exacerbate hyperinflammation in the progression to severe COVID-19 through diverse mechanisms. Further understanding of the roles of type I interferon at different stages of infection and in patients with mild versus severe COVID-19 will provide insights for the therapeutic use of interferon administration or JAK inhibitors in patients with COVID-19.
In this Comment, Jeong Seok Lee and Eui-Cheol Shin discuss contradictory results regarding the downregulation or upregulation of type I interferon responses in patients with COVID-19 and the implications for therapies that target this pathway. |
| doi_str_mv | 10.1038/s41577-020-00429-3 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8824445</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A636481492</galeid><sourcerecordid>A636481492</sourcerecordid><originalsourceid>FETCH-LOGICAL-c672t-311d6220ee4ba2d7facee8f87e9f4051c32aa1b3302cf58ebffa5f950af1be1a3</originalsourceid><addsrcrecordid>eNp9kl1rFDEUhoMo9kP_gBcyIBR6MW2-ZpLxQiir1YVCQau3IZM92U2ZmYxJpth_b9qt2w4UyUXCeZ_zJjm8CL0j-IRgJk8jJ5UQJaa4xJjTpmQv0D7hgpdEcPJyd2ZsDx3EeI0xqbPyGu0xKqQUWO6j86sNFOl2hGJZuCFBsBD8UASIox8i5FqxuPy1_FyS5mPh-rFzRieXpcL6UKQAOvUwpDfoldVdhLcP-yH6ef7lavGtvLj8ulycXZSmFjSVjJBVTSkG4K2mK2G1AZBWCmgsxxUxjGpNWsYwNbaS0FqrK9tUWFvSAtHsEH3a-o5T28PK5KuD7tQYXK_DrfLaqbkyuI1a-xslJeWcV9ngw4NB8L8niEld-ykM-c2KciEkJVKyR2qtO1BusD6bmd5Fo85qVnNJeEMzdfIMldcKemf8ANbl-qzheNaQmQR_0lpPMarlj-9z9ugJuwHdpU303XQ__DlIt6AJPsYAdjcNgtVdTtQ2JyrnRN3nRN198P3TOe5a_gUjA2wLxCwNawiPc_qP7V9_EsYh</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2477821883</pqid></control><display><type>article</type><title>The type I interferon response in COVID-19: implications for treatment</title><source>MEDLINE</source><source>Nature Journals Online</source><source>SpringerLink Journals - AutoHoldings</source><creator>Lee, Jeong Seok ; Shin, Eui-Cheol</creator><creatorcontrib>Lee, Jeong Seok ; Shin, Eui-Cheol</creatorcontrib><description>Despite early reports to the contrary, there is increasing evidence that patients with severe COVID-19 have a robust type I interferon response, which contrasts with the delayed, possibly suppressed, interferon response seen early in infection. A robust type I interferon response could exacerbate hyperinflammation in the progression to severe COVID-19 through diverse mechanisms. Further understanding of the roles of type I interferon at different stages of infection and in patients with mild versus severe COVID-19 will provide insights for the therapeutic use of interferon administration or JAK inhibitors in patients with COVID-19.
In this Comment, Jeong Seok Lee and Eui-Cheol Shin discuss contradictory results regarding the downregulation or upregulation of type I interferon responses in patients with COVID-19 and the implications for therapies that target this pathway.</description><identifier>ISSN: 1474-1733</identifier><identifier>EISSN: 1474-1741</identifier><identifier>DOI: 10.1038/s41577-020-00429-3</identifier><identifier>PMID: 32788708</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/250/127/1212 ; 692/699/255/2514 ; Azetidines - therapeutic use ; Betacoronavirus - immunology ; Betacoronavirus - pathogenicity ; Biological response modifiers ; Biomedical and Life Sciences ; Biomedicine ; Comment ; Coronavirus Infections - drug therapy ; Coronavirus Infections - immunology ; Coronavirus Infections - pathology ; Coronavirus Infections - virology ; Coronaviruses ; COVID-19 ; Gene Expression Regulation ; Health aspects ; Humans ; Immunity, Cellular - drug effects ; Immunity, Humoral - drug effects ; Immunology ; Infection ; Interferon ; Interferon Regulatory Factors - genetics ; Interferon Regulatory Factors - immunology ; Interferon-alpha - genetics ; Interferon-alpha - immunology ; Interferon-alpha - therapeutic use ; Interferon-beta - genetics ; Interferon-beta - immunology ; Interferon-beta - therapeutic use ; Interferons - genetics ; Interferons - immunology ; Interferons - therapeutic use ; Interleukin-1 - genetics ; Interleukin-1 - immunology ; Interleukin-6 - antagonists & inhibitors ; Interleukin-6 - genetics ; Interleukin-6 - immunology ; Janus Kinase 1 - antagonists & inhibitors ; Janus Kinase 1 - genetics ; Janus Kinase 1 - immunology ; Lung - drug effects ; Lung - immunology ; Lung - pathology ; Pandemics ; Pneumonia, Viral - drug therapy ; Pneumonia, Viral - immunology ; Pneumonia, Viral - pathology ; Pneumonia, Viral - virology ; Purines ; Pyrazoles ; SARS-CoV-2 ; Severity of Illness Index ; Sulfonamides - therapeutic use ; Tumor Necrosis Factor-alpha - genetics ; Tumor Necrosis Factor-alpha - immunology</subject><ispartof>Nature reviews. Immunology, 2020-10, Vol.20 (10), p.585-586</ispartof><rights>Springer Nature Limited 2020</rights><rights>COPYRIGHT 2020 Nature Publishing Group</rights><rights>Springer Nature Limited 2020.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c672t-311d6220ee4ba2d7facee8f87e9f4051c32aa1b3302cf58ebffa5f950af1be1a3</citedby><cites>FETCH-LOGICAL-c672t-311d6220ee4ba2d7facee8f87e9f4051c32aa1b3302cf58ebffa5f950af1be1a3</cites><orcidid>0000-0002-6308-9503 ; 0000-0001-8261-7044</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41577-020-00429-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41577-020-00429-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,780,784,885,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32788708$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Jeong Seok</creatorcontrib><creatorcontrib>Shin, Eui-Cheol</creatorcontrib><title>The type I interferon response in COVID-19: implications for treatment</title><title>Nature reviews. Immunology</title><addtitle>Nat Rev Immunol</addtitle><addtitle>Nat Rev Immunol</addtitle><description>Despite early reports to the contrary, there is increasing evidence that patients with severe COVID-19 have a robust type I interferon response, which contrasts with the delayed, possibly suppressed, interferon response seen early in infection. A robust type I interferon response could exacerbate hyperinflammation in the progression to severe COVID-19 through diverse mechanisms. Further understanding of the roles of type I interferon at different stages of infection and in patients with mild versus severe COVID-19 will provide insights for the therapeutic use of interferon administration or JAK inhibitors in patients with COVID-19.
In this Comment, Jeong Seok Lee and Eui-Cheol Shin discuss contradictory results regarding the downregulation or upregulation of type I interferon responses in patients with COVID-19 and the implications for therapies that target this pathway.</description><subject>631/250/127/1212</subject><subject>692/699/255/2514</subject><subject>Azetidines - therapeutic use</subject><subject>Betacoronavirus - immunology</subject><subject>Betacoronavirus - pathogenicity</subject><subject>Biological response modifiers</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Comment</subject><subject>Coronavirus Infections - drug therapy</subject><subject>Coronavirus Infections - immunology</subject><subject>Coronavirus Infections - pathology</subject><subject>Coronavirus Infections - virology</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Gene Expression Regulation</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Immunity, Cellular - drug effects</subject><subject>Immunity, Humoral - drug effects</subject><subject>Immunology</subject><subject>Infection</subject><subject>Interferon</subject><subject>Interferon Regulatory Factors - genetics</subject><subject>Interferon Regulatory Factors - immunology</subject><subject>Interferon-alpha - genetics</subject><subject>Interferon-alpha - immunology</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Interferon-beta - genetics</subject><subject>Interferon-beta - immunology</subject><subject>Interferon-beta - therapeutic use</subject><subject>Interferons - genetics</subject><subject>Interferons - immunology</subject><subject>Interferons - therapeutic use</subject><subject>Interleukin-1 - genetics</subject><subject>Interleukin-1 - immunology</subject><subject>Interleukin-6 - antagonists & inhibitors</subject><subject>Interleukin-6 - genetics</subject><subject>Interleukin-6 - immunology</subject><subject>Janus Kinase 1 - antagonists & inhibitors</subject><subject>Janus Kinase 1 - genetics</subject><subject>Janus Kinase 1 - immunology</subject><subject>Lung - drug effects</subject><subject>Lung - immunology</subject><subject>Lung - pathology</subject><subject>Pandemics</subject><subject>Pneumonia, Viral - drug therapy</subject><subject>Pneumonia, Viral - immunology</subject><subject>Pneumonia, Viral - pathology</subject><subject>Pneumonia, Viral - virology</subject><subject>Purines</subject><subject>Pyrazoles</subject><subject>SARS-CoV-2</subject><subject>Severity of Illness Index</subject><subject>Sulfonamides - therapeutic use</subject><subject>Tumor Necrosis Factor-alpha - genetics</subject><subject>Tumor Necrosis Factor-alpha - immunology</subject><issn>1474-1733</issn><issn>1474-1741</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kl1rFDEUhoMo9kP_gBcyIBR6MW2-ZpLxQiir1YVCQau3IZM92U2ZmYxJpth_b9qt2w4UyUXCeZ_zJjm8CL0j-IRgJk8jJ5UQJaa4xJjTpmQv0D7hgpdEcPJyd2ZsDx3EeI0xqbPyGu0xKqQUWO6j86sNFOl2hGJZuCFBsBD8UASIox8i5FqxuPy1_FyS5mPh-rFzRieXpcL6UKQAOvUwpDfoldVdhLcP-yH6ef7lavGtvLj8ulycXZSmFjSVjJBVTSkG4K2mK2G1AZBWCmgsxxUxjGpNWsYwNbaS0FqrK9tUWFvSAtHsEH3a-o5T28PK5KuD7tQYXK_DrfLaqbkyuI1a-xslJeWcV9ngw4NB8L8niEld-ykM-c2KciEkJVKyR2qtO1BusD6bmd5Fo85qVnNJeEMzdfIMldcKemf8ANbl-qzheNaQmQR_0lpPMarlj-9z9ugJuwHdpU303XQ__DlIt6AJPsYAdjcNgtVdTtQ2JyrnRN3nRN198P3TOe5a_gUjA2wLxCwNawiPc_qP7V9_EsYh</recordid><startdate>20201001</startdate><enddate>20201001</enddate><creator>Lee, Jeong Seok</creator><creator>Shin, Eui-Cheol</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7QR</scope><scope>7RV</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6308-9503</orcidid><orcidid>https://orcid.org/0000-0001-8261-7044</orcidid></search><sort><creationdate>20201001</creationdate><title>The type I interferon response in COVID-19: implications for treatment</title><author>Lee, Jeong Seok ; Shin, Eui-Cheol</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c672t-311d6220ee4ba2d7facee8f87e9f4051c32aa1b3302cf58ebffa5f950af1be1a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>631/250/127/1212</topic><topic>692/699/255/2514</topic><topic>Azetidines - therapeutic use</topic><topic>Betacoronavirus - immunology</topic><topic>Betacoronavirus - pathogenicity</topic><topic>Biological response modifiers</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Comment</topic><topic>Coronavirus Infections - drug therapy</topic><topic>Coronavirus Infections - immunology</topic><topic>Coronavirus Infections - pathology</topic><topic>Coronavirus Infections - virology</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Gene Expression Regulation</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Immunity, Cellular - drug effects</topic><topic>Immunity, Humoral - drug effects</topic><topic>Immunology</topic><topic>Infection</topic><topic>Interferon</topic><topic>Interferon Regulatory Factors - genetics</topic><topic>Interferon Regulatory Factors - immunology</topic><topic>Interferon-alpha - genetics</topic><topic>Interferon-alpha - immunology</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Interferon-beta - genetics</topic><topic>Interferon-beta - immunology</topic><topic>Interferon-beta - therapeutic use</topic><topic>Interferons - genetics</topic><topic>Interferons - immunology</topic><topic>Interferons - therapeutic use</topic><topic>Interleukin-1 - genetics</topic><topic>Interleukin-1 - immunology</topic><topic>Interleukin-6 - antagonists & inhibitors</topic><topic>Interleukin-6 - genetics</topic><topic>Interleukin-6 - immunology</topic><topic>Janus Kinase 1 - antagonists & inhibitors</topic><topic>Janus Kinase 1 - genetics</topic><topic>Janus Kinase 1 - immunology</topic><topic>Lung - drug effects</topic><topic>Lung - immunology</topic><topic>Lung - pathology</topic><topic>Pandemics</topic><topic>Pneumonia, Viral - drug therapy</topic><topic>Pneumonia, Viral - immunology</topic><topic>Pneumonia, Viral - pathology</topic><topic>Pneumonia, Viral - virology</topic><topic>Purines</topic><topic>Pyrazoles</topic><topic>SARS-CoV-2</topic><topic>Severity of Illness Index</topic><topic>Sulfonamides - therapeutic use</topic><topic>Tumor Necrosis Factor-alpha - genetics</topic><topic>Tumor Necrosis Factor-alpha - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Jeong Seok</creatorcontrib><creatorcontrib>Shin, Eui-Cheol</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Chemoreception Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nature reviews. Immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Jeong Seok</au><au>Shin, Eui-Cheol</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The type I interferon response in COVID-19: implications for treatment</atitle><jtitle>Nature reviews. Immunology</jtitle><stitle>Nat Rev Immunol</stitle><addtitle>Nat Rev Immunol</addtitle><date>2020-10-01</date><risdate>2020</risdate><volume>20</volume><issue>10</issue><spage>585</spage><epage>586</epage><pages>585-586</pages><issn>1474-1733</issn><eissn>1474-1741</eissn><abstract>Despite early reports to the contrary, there is increasing evidence that patients with severe COVID-19 have a robust type I interferon response, which contrasts with the delayed, possibly suppressed, interferon response seen early in infection. A robust type I interferon response could exacerbate hyperinflammation in the progression to severe COVID-19 through diverse mechanisms. Further understanding of the roles of type I interferon at different stages of infection and in patients with mild versus severe COVID-19 will provide insights for the therapeutic use of interferon administration or JAK inhibitors in patients with COVID-19.
In this Comment, Jeong Seok Lee and Eui-Cheol Shin discuss contradictory results regarding the downregulation or upregulation of type I interferon responses in patients with COVID-19 and the implications for therapies that target this pathway.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>32788708</pmid><doi>10.1038/s41577-020-00429-3</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0002-6308-9503</orcidid><orcidid>https://orcid.org/0000-0001-8261-7044</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1474-1733 |
| ispartof | Nature reviews. Immunology, 2020-10, Vol.20 (10), p.585-586 |
| issn | 1474-1733 1474-1741 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8824445 |
| source | MEDLINE; Nature Journals Online; SpringerLink Journals - AutoHoldings |
| subjects | 631/250/127/1212 692/699/255/2514 Azetidines - therapeutic use Betacoronavirus - immunology Betacoronavirus - pathogenicity Biological response modifiers Biomedical and Life Sciences Biomedicine Comment Coronavirus Infections - drug therapy Coronavirus Infections - immunology Coronavirus Infections - pathology Coronavirus Infections - virology Coronaviruses COVID-19 Gene Expression Regulation Health aspects Humans Immunity, Cellular - drug effects Immunity, Humoral - drug effects Immunology Infection Interferon Interferon Regulatory Factors - genetics Interferon Regulatory Factors - immunology Interferon-alpha - genetics Interferon-alpha - immunology Interferon-alpha - therapeutic use Interferon-beta - genetics Interferon-beta - immunology Interferon-beta - therapeutic use Interferons - genetics Interferons - immunology Interferons - therapeutic use Interleukin-1 - genetics Interleukin-1 - immunology Interleukin-6 - antagonists & inhibitors Interleukin-6 - genetics Interleukin-6 - immunology Janus Kinase 1 - antagonists & inhibitors Janus Kinase 1 - genetics Janus Kinase 1 - immunology Lung - drug effects Lung - immunology Lung - pathology Pandemics Pneumonia, Viral - drug therapy Pneumonia, Viral - immunology Pneumonia, Viral - pathology Pneumonia, Viral - virology Purines Pyrazoles SARS-CoV-2 Severity of Illness Index Sulfonamides - therapeutic use Tumor Necrosis Factor-alpha - genetics Tumor Necrosis Factor-alpha - immunology |
| title | The type I interferon response in COVID-19: implications for treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T13%3A33%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20type%20I%20interferon%20response%20in%20COVID-19:%20implications%20for%20treatment&rft.jtitle=Nature%20reviews.%20Immunology&rft.au=Lee,%20Jeong%20Seok&rft.date=2020-10-01&rft.volume=20&rft.issue=10&rft.spage=585&rft.epage=586&rft.pages=585-586&rft.issn=1474-1733&rft.eissn=1474-1741&rft_id=info:doi/10.1038/s41577-020-00429-3&rft_dat=%3Cgale_pubme%3EA636481492%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2477821883&rft_id=info:pmid/32788708&rft_galeid=A636481492&rfr_iscdi=true |